Solid Biosciences (SLDB) Stock Price, News & Analysis

Company Overview

Solid Biosciences Inc. is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector. In addition to SGT‐001, the company is advancing next-generation programs including SGT-003, a CRISPR/Cas9‐based gene editing approach aimed at correcting specific dystrophin gene mutations, and proprietary assays for sensitive detection of dystrophin expression in muscle tissue.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Solid Biosciences leverages partnerships with academic institutions and patient advocacy groups to support clinical development and expand its understanding of DMD biology. Its clinical studies have been conducted at sites across the United States and Europe, reflecting the global nature of DMD research and the need for broad patient enrollment in rare-disease trials.

Under the leadership of Chief Executive Officer Ilan Ganot, Solid Biosciences maintains a network of research and manufacturing collaborations to enhance vector production and assay development. The company’s mission remains to deliver transformative therapies to DMD patients by advancing innovative genetic medicines and building the infrastructure required for efficient clinical translation.

Key Stats

• Today's Range: $8.24 to $8.63
• 50-Day Range: $6.41 to $11.15
• 52-Week Range: $3.79 to $11.45
• Volume: 45,273 shs
• Average Volume: 1.44 million shs
• Market Capitalization: $791.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.11
• Consensus Rating: Moderate Buy

Solid Biosciences Stock Analysis - MarketRank™

Solid Biosciences scored higher than 54% of companies evaluated by MarketBeat, and ranked 387th out of 833 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Solid Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 1 strong buy rating, 9 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Solid Biosciences has a consensus price target of $17.11, representing about 101.5% upside from its current price of $8.49.

Amount of Analyst Coverage

Solid Biosciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Solid Biosciences are expected to decrease in the coming year, from ($1.90) to ($1.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Solid Biosciences is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Solid Biosciences is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Solid Biosciences has a P/B Ratio of 3.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.44% of the float of Solid Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Solid Biosciences has a short interest ratio ("days to cover") of 11.18, which indicates bearish sentiment.

Change versus previous month

Short interest in Solid Biosciences has recently decreased by 3.29%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Solid Biosciences does not currently pay a dividend.

Dividend Growth

Solid Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.38

News Sentiment

Solid Biosciences has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Solid Biosciences this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for SLDB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Solid Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.66% of the stock of Solid Biosciences is held by insiders.

Percentage Held by Institutions

81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 7/31/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLDB
• CIK: 1707502
• Web: www.solidbio.com
• Phone: (617) 337-4680
• Fax: N/A
• Employees: 100
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Solid Biosciences: $17.11
• High Price Target: $26.00
• Low Price Target: $9.00
• Potential Upside/Downside: +106.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$174.32 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -73.42%
• Return on Assets: -61.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.10
• Quick Ratio: 13.10

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.28 per share
• Price / Book: 3.64

Miscellaneous

• Outstanding Shares: 98,450,000
• Free Float: 95,831,000
• Market Cap: $817.82 million
• Optionable: Optionable
• Beta: 2.36